Context.-Women who have been treated for high-grade cervical or vaginal intraepithelial neoplasia (CIN or VAIN) or invasive carcinoma are at risk for recurrent/persistent disease and require long-term monitoring. The role of human papillomavirus (HPV) testing in this setting is unclear.
test result was positive in 33% of the patients. Follow-up biopsy was available for 17 of these patients (52%) and for 25 of the 67 patients (37%) with a negative HC2 result. A total of 5 of the patients (29%) with a positive HC2 result and 2 of the patients (8%) with a negative HC2 result had CIN/VAIN 3 on follow-up biopsy, a statistically insignificant difference (P ¼ .10). Human papillomavirus 16/18 genotypes were detected in the CIN/VAIN 2þ lesions of 5 patients with a negative HC2 result.
Conclusions.-HC2 yielded a false-negative rate of 8% for CIN 3. HC2 testing therefore may not be sufficient for triage of patients with an ASC-US Papanicolaou test result. Patients with ASC-US during long-term posttherapy followup need close monitoring, with colposcopic evaluation if clinically indicated.
(Arch Pathol Lab Med. 2015;139:219-224; doi: 10.5858/ arpa.2013-0291-OA) W omen who have been treated for high-grade cervical or vaginal intraepithelial neoplasia (CIN/VAIN 2 or 3, referred to here as CIN/VAIN 2þ) or invasive carcinoma are at risk for recurrent/persistent lesions (5%-15%) [1] [2] [3] [4] [5] and at higher than normal risk for invasive carcinoma. 6, 7 Posttherapy follow-up monitoring is critical for early detection of these recurrent/residual precancerous or cancerous lesions. According to the 2006 guidelines of the American Society for Colposcopy and Cervical Pathology (ASCCP), acceptable posttherapy management options for women with CIN 2þ include human papillomavirus (HPV) DNA testing or Papanicolaou test (Pap) cytologic testing with or without colposcopy at 6-to 12-month intervals. 8 The 2012 clinical management guidelines for screening for cervical cancer issued by the American College of Obstetricians and Gynecologists, as well as the 2012 clinical pathology screening guidelines for the prevention and early detection of cervical cancer, recommended screening for 20 years after initial posttherapy surveillance. 9, 10 Recently, the 2012 updated ASCCP consensus guidelines for the management of abnormal cervical cancer screening test results and cancer precursors further recommended HPV and Pap cytology cotesting for posttherapy follow-up.
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DNA testing for high-risk HPV genotypes has been reported to be highly sensitive in detecting recurrent/ residual CIN/VAIN 2þ. [12] [13] [14] [15] [16] [17] A commercial HPV testing assay, Hybrid Capture 2 (HC2; Qiagen, Valencia, California), which collectively detects 13 high-risk HPV genotypes, was reported to be more sensitive than Pap cytology in predicting CIN/VAIN 2þ in posttherapy follow-up.
Combined HC2 HPV DNA testing and Pap cytology has even greater sensitivity in detecting recurrent/residual CIN/ VAIN 2þ lesions in this setting. 1, [19] [20] [21] Pap cytology is routinely used at our hospital for followup monitoring of women who have been treated for CIN/ VAIN 2þ or cervical carcinoma. Colposcopic evaluation is usually required for patients who have Pap results of abnormal squamous cells of undetermined significance, cannot exclude high-grade squamous intraepithelial lesion (ASC-H); low-grade squamous intraepithelial lesion (LSIL); or high-grade squamous intraepithelial lesion (HSIL). However, management of cases of abnormal squamous cells of undetermined significance (ASC-US) during posttherapy follow-up can be challenging and complicated. Chemotherapy and/or radiation therapy can cause treatment effects in Pap specimen cells that mimic dysplastic cells and make interpretation difficult. Moreover, atrophy is frequent in the relatively older cancer patient population. Together, these changes may cause inadequate sampling, leading to an ASC-US Pap result. To better predict the risk of recurrent/residual CIN/VAIN 2þ lesions, the HC2 HPV DNA test has been used in many Pap test cases diagnosed as ASC-US in our hospital.
In most published studies using the HC2 assay, the sensitivities for CIN 2þ were compared between HC2 and Pap cytology for all cytologic diagnoses of ASC-US, LSIL, and HSIL. 1, 19, 20 The risk of CIN 2þ after colposcopic examination in women who had an ASC-US Pap result with HC2 result has been reported previously. 22 However, it remains unclear whether HC2 HPV testing is efficient in predicting CIN 2þ in women with ASC-US during posttherapy follow-up. The aim of the study was to determine the clinical performance of HC2 HPV testing for predicting recurrence/residual disease in women with an ASC-US Pap result following treatment for CIN/VAIN 2þ or invasive carcinoma. In this study, we retrospectively reviewed posttherapy follow-up data on women who had an ASC-US Pap result and underwent HC2 HPV DNA testing. All of the patients had been treated for a CIN/VAIN 2þ lesion or invasive carcinoma and monitored after therapy by the Department of Gynecologic Oncology and Reproductive Medicine at our institution.
MATERIALS AND METHODS

Patient Selection
We retrospectively reviewed data on 1308 patients who had an ASC-US Pap test result reviewed by the Department of Pathology at our institution during the period 2006-2009 and underwent reflex HC2 HPV DNA testing. Of these, a total of 100 women were qualified for the study on the basis of our selection criteria, which included the following: (1) a history of treatment for either CIN/ VAIN 2þ or invasive carcinoma; (2) a posttherapy ASC-US Pap result and HC2 HPV DNA result; and (3) availability of follow-up test results, including biopsy findings or Pap cytology results with or without HC2 HPV DNA retest. Women without either a followup biopsy result or Pap cytology result were excluded from the study. The protocol for this study was approved by our center's Institutional Review Board.
Pap Cytology and Biopsy Specimens
SurePath Pap specimens (BD Diagnostics-TriPath Imaging, Burlington, North Carolina) were screened by cytotechnologists and verified by cytopathologists following the Bethesda System terminology for reporting Pap test results. 23 The follow-up biopsy specimens were processed and interpreted in the Department of Pathology at our institution.
HPV DNA Testing
Human papillomavirus DNA was analyzed by the Hybrid Capture 2 assay (Qiagen, Valencia, California), which collectively tests for 13 high-risk HPV DNA types. The residual SurePath specimen was sent to Quest Diagnostics (Houston, Texas) for HC2 HPV testing. For HPV genotyping, DNA was extracted from biopsy or SurePath Pap specimens using the DNeasy kit (catalog 69506, Qiagen) according to the manufacturer's instructions. Human papillomavirus genotyping was done with EasyChip HPV Blot (King Car Yuanshan Research Institute, I-Lan, Taiwan) as described previously. 24 The EasyChip HPV Blot was designed to detect 38 HPV types (HPV types 6, 11, 16, 18, 26, 31, 32, 33, 
Patient Follow-up
Follow-up data were collected at a mean interval of 30 months after the ASC-US Pap result and HC2 testing (range, 0-67 months) were obtained.
Statistical Analysis
Descriptive statistics were used for data analysis; the Fisher exact test was employed to assess the association between categoric variables. P values (2-sided test) less than .05 were considered significant. All computations were carried out using SAS version 8.0 (SAS Institute, Cary, North Carolina).
RESULTS
Patients and Clinical History
Patient ages at the time of the ASC-US Pap test result, during posttherapy follow-up, ranged from 15 to 82 years, with a mean of 47 years. Of the 100 patients, 56 were white, 22 were Hispanic, 17 were African American, and 5 were Asian. Their clinical histories included invasive squamous carcinoma (38%); cervical adenocarcinoma, including 2 cases of adenocarcinoma in situ (10%); CIN 2/3 (35%); VAIN 2/3 (6%); and unclassified high-grade dysplasia (11%). The patients underwent one or more treatments, including surgical treatment, such as cold-knife conization, loop electrosurgical excision procedures, or hysterectomy; ablation, such as cryoablation or laser ablation; and/or chemotherapy and/or radiation therapy (Table 1) . Mean interval from initial diagnosis to ASC-US Pap test result and HC2 testing was 87 months (range, 5-420 months).
HC2 HPV DNA Testing Results and Patient Follow-up
Of the 100 ASC-US Pap test specimens, 56 were cervical and 44 were vaginal specimens. A total of 17 of 56 cervical specimens (30%) and 16 of 44 vaginal specimens (36%) were positive for HPV using the HC2 assay. A total of 25 of the 67 patients (37%) with a negative HC2 result and 17 of the 33 patients (52%) with a positive HC2 result underwent follow-up biopsy ( Table 2 ). The mean interval between the Pap/HC2 testing and the follow-up biopsy was 5.1 months. Of these 42 biopsies, 27 were cervical and 15 were vaginal. Of the 27 cervical follow-up biopsies, 11 were from patients with a positive HC2 result and 16 were from patients with a negative HC2 result. A CIN 3 lesion was observed in 4 patients with a positive HC2 result and 1 patient with a negative HC2 result. The difference in rate of CIN 3 on follow-up biopsy between the two groups was not statistically significant (P ¼ .13). Of the 15 vaginal followup biopsies, 6 were from patients with a positive HC2 result and 9 were from patients with a negative HC2 result. A VAIN 3 lesion was diagnosed in 1 patient with a positive HC2 result and 1 patient with a negative HC2 result. The difference in rate of CIN/VAIN 3 on follow-up biopsy between the two groups was not statistically significant (P . .99). The risk of CIN/VAIN 3 among patients with a negative HC2 result was 8% (2 of 25), and among patients with a positive HC2 result it was 29% (5 of 17; P ¼ .10). The risk of CIN/VAIN 2þ was similar in women with a positive HC2 result (29%) and those with a negative HC2 result (28%).
Follow-up Pap cytology results for the 58 patients without biopsy follow-up are illustrated in Table 3 . Of these 58 patients, none had an HSIL Pap result. A total of 42 patients had a negative HC2 result, and 3 of those (7%) had ASC-US/LSIL on follow-up Pap cytology. Of the 16 patients with a positive HC2 result, 7 (44%) had ASC-US/LSIL on followup Pap (Table 3) . The difference between the two groups for the rates of ASC-US/LSIL on follow-up Pap was statistically significant (P ¼ .003).
HC2 HPV DNA retest data were available for 29 patients with a baseline negative HC2 result and 17 patients with a baseline positive HC2 result. Of the 29 patients with a baseline negative HC2 result, 1 (4%) had a follow-up positive HC2 result. Of the 17 patients with a baseline positive HC2 result, 3 (18%) had a follow-up positive HC2 result.
HPV Genotyping
A total of 7 patients with a negative HC2 result had a follow-up biopsy showing CIN/VAIN 2þ. Biopsy findings were CIN 2 in 2 patients, CIN 3 in 1 patient, VAIN 2 in 3 patients, and VAIN 3 in 1 patient. Human papillomavirus genotyping was done on 6 of the 7 biopsy specimens, 5 of which demonstrated high-risk HPV genotypes, including HPV 16/18 (Table 4) . Of these 7 patients with an ASC-US Pap result and a negative HC2 result, only 1 patient (case number 3 in Table 4 ) underwent biopsy on the basis of ASC-US Pap result only. The other 6 patients underwent follow-up colposcopic evaluation and biopsy on the basis of previous cytology or biopsy results from outside hospitals/ institutions, either abnormal Pap and HC2 results or abnormal biopsy results (Table 4) .
HC2 Testing Efficacy
Of 25 biopsies from patients with a negative HC2 result, 2 were CIN/VAIN 3, representing a false-negative rate of 8%. In predicting CIN/VAIN 3 lesions, HC2 showed 71.4% sensitivity, 65.7% specificity, 29.4% positive predictive value, and 92.0% negative predictive value.
COMMENT
In this retrospective study, we reviewed data on 100 patients who had an ASC-US Pap test result and underwent HC2 HPV DNA testing during long-term posttherapy follow-up monitoring. We found that the risk of CIN/VAIN 3 in women with a positive HC2 result (29%) was higher than that in women with a negative HC2 result (8%). However, the rates of recurrent/residual CIN/VAIN 3 between the two groups were not significantly different (P ¼ .10). The risk of CIN 2þ was similar in women with a positive HC2 result (29%) and those with a negative HC2 result (28%). Human papillomavirus 16/18 genotypes were detected in 5 biopsies from patients with a negative HC2 result and recurrent/residual CIN/VAIN 2þ, indicating falsenegative HC2 results. Our findings demonstrate that the HC2 assay has relatively low sensitivity for triaging patients with an ASC-US Pap test result during long-term posttherapy follow-up. Consequently, patients with an ASC-US Pap test result and a negative HC2 result during posttherapy follow-up require further evaluation, such as colposcopic examination or repeat Pap/HPV testing, within a short interval of time.
We observed a relatively high rate of recurrent/residual CIN/VAIN 2þ in these 100 women (12%), indicating the considerable risk for recurrent/residual CIN/VAIN 2þ in patients with ASC-US during long-term posttherapy follow-up. In short-term follow-up, rates of recurrent/ residual CIN/VAIN 2þ ranged from 7% to 17.9%. [18] [19] [20] [25] [26] [27] There are very few reports of long-term follow-up monitoring studies. In a large cohort of patients treated for CIN 3, Melnikow et al 5 reported a rate of recurrent/ residual CIN 2þ of 14%. Kreimer et al 17 reported a 1.7% rate of recurrent/residual CIN 2þ in a long-term follow-up study.
To the best of our knowledge, our study is the first report on HC2 efficacy for women with an ASC-US Pap result during long-term posttherapy monitoring. In most published studies of posttherapy follow-up monitoring, authors compare the efficacy of HC2 testing with that of Pap test cytology only for all cases diagnosed as ASC-US, LSIL, and HSIL. Most of these studies reported only short-term posttherapy follow-up intervals (,24 months). 13 The pooled sensitivity of HC2 for CIN 2þ in these studies was 79% to 90.7%. 13, 14 It has been well documented that women with an ASC-H, LSIL, or HSIL Pap test result have a higher risk of CIN 2þ and a higher positive rate of high-risk HPV than those with an ASC-US Pap result. 28 Therefore, the relatively high sensitivity of HC2 in these reported studies may represent the sensitivity of HC2 in all patients with ASC-US, ASC-H, LSIL, or HSIL.
Human papillomavirus testing is more clinically relevant in women with an ASC-US Pap test result during posttherapy follow-up monitoring than in individuals with an ASC-H, LSIL, or HSIL Pap test result during that period. In a screening population (ASCUS-LSIL Triage Study [ALTS]), Safaeian et al 29 reported the risk of CIN 3 associated with HC2 status in women with ASC-US. They observed a lower risk of CIN 3 in women with an ASC-US Pap test result and a negative HC2 result (1.4%) than in those with an ASC-US Pap test result and a positive HC2 result (15.2%). As part of the ALTS study, Walker et al 22 reported a higher risk of CIN 3 in women who had an ASC-US Pap test result and a positive HC2 result (10.8%) while being monitored after colposcopy than in those individuals who had an ASC-US Pap test result and a negative HC2 result (5%). In our study of posttherapy follow-up monitoring, risk of CIN/VAIN 3 was higher in women with ASC-US/HC2-positive results (29%) than in women with ASC-US/HC2-negative results (8%). The high risk of CIN/VAIN 3 in our cohort is mainly due to the higher risk in patients with a significant history of cervical/vaginal dysplasia or carcinoma than in a screening population. Although we observed an HC2 sensitivity for CIN 3 (5 of 7; 71%) comparable with that reported by Safaeian et al 29 (5 of 7; 71.4%) in the screening population, our patients had a much higher risk level (29.4%) than the ALTS screening population (3.8%). However, the sensitivity of HC2 for CIN 2þ in our study was lower (41%) than that in the ALTS study (67%). Notably, unlike the reflex HPV testing for women with ASC-US Pap results, or Pap and HPV coscreening for women 30 years and older in a screening population, HPV testing for posttherapy follow-up has been considered an off-label application of the Food and Drug Administrationapproved test, mainly due to lack of clinical trial studies. Recently, Katki et al, 30 in a follow-up study of 3273 women who were treated for CIN 2þ or adenocarcinoma in situ at the Kaiser Permanente Medical Care Program (Oakland, California), reported a lower 5-year CIN 2þ risk (1.5%) after 2 negative cotest results with HPV and Pap cytology than after 2 negative HPV (2.7%) or Pap cytology (2.7%) tests, indicating that HPV and Pap cotesting is more efficient than HPV testing or Pap cytology alone for predicting CIN 2þ. These findings and our observation support HPV and Pap cytology cotesting during posttherapy follow-up, which was recently recommended by the ASCCP.
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The reasons for the HC2 false-negative results in our study are unclear. Several factors may affect the sensitivity of the HC2 assay in posttherapy follow-up monitoring. The major factor may be the older mean age of the patient population in our hospital. Stoler et al, 31 in a screening population of women with ASC-US, reported positivity for high-risk HPV decreased from 54.1% in women ages 21 to 29 years to 14.7% in women ages 40 to 49 years. HC2 sensitivity also declined with age, from 93.3% in women ages 21 to 29 years to 67.7% in women 40 years and older. 32 Einstein et al, 33 using the Cervista HPV HR testing assay, reported similar findings, that sensitivity declined with age. In our cohort, the mean age was 47 years, older than the mean ages of patient cohorts in previously published reports. Park et al 34 also reported a relatively low HC2 sensitivity in predicting CIN 2þ in a cohort with a mean age of 41 years. Although the cause of the lower sensitivity of HPV testing for CIN 2þ in older women compared with younger women is still unknown, it might be associated with a lower viral load in the former. 35 We speculated that the reduced sensitivity of HC2 seen in our study could be due to the presence of scant dysplastic cells, leading to a low viral load that is suboptimal for HC2 testing. This reduced tissue acquisition could be related to the atrophy in older patients or therapy effects.
Reduced sensitivity in our group may also be related to the degree of analytic sensitivity of the HC2 HPV DNA assay. Unlike polymerase chain reaction (PCR)-based HPV assays, the HC2 assay does not rely on target amplification, and thus its analytic sensitivity is lower than that of the PCR-based assays. In a study with the largest reported cohort of patients in posttherapy follow-up, Kreimer et al 20 compared the HC2 assay with a PCR assay in predicting recurrent/residual CIN 2þ. The results showed that the sensitivity of the PCR assay (97%) was higher than that of the HC2 assay (91%). High sensitivity of PCR-based HPV DNA testing for posttherapy follow-up was also documented by other investigators. 13, 36 Therefore, we speculate that the low sensitivity of HC2 testing in predicting CIN/VAIN 2þ in our study might be attributed in part to the relatively low analytic sensitivity of the HC2 assay. We used a PCRbased assay to test 3 residual Pap test specimens from patients with a negative HC2 result but CIN/VAIN 2þ on follow-up biopsy, and all 3 samples were positive for highrisk HPV types (data not shown). The tissue specimens showing CIN/VAIN 2þ from patients with a negative HC2 result exhibited high-risk HPV types, including HPV 16/18. These findings may reflect the differential sensitivities of HC2 and PCR-based HPV assays.
Another possible factor in the high HC2 false-negative rate is the off-label use of the HC2 assay with SurePath specimens. The SurePath collecting medium is an alcoholbased preservative containing a trace amount of formalin. It has been recognized that formalin-containing fixatives can cause cross-linking of nucleic acid to protein, which interferes with enzymatic lysis of fixed cells during DNA extraction for molecular testing, resulting in a low yield of DNA extraction. A study comparing recovery of nucleic acids in cell lines stored in SurePath or ThinPrep medium showed a low yield of DNA extracted from cells in SurePath medium without an appropriate enzyme treatment. The yield of DNA was significantly improved with proteinase K treatment. 37 Another recently published study showed that SurePath specimens treated with combined proteinase K and heat to reverse formalin-induced cross-linking were not statistically different in the reproducibility than ThinPrep specimens for HPV DNA testing using a PCR assay. 38 In addition, because the use of HC2 HPV testing in SurePath Pap specimens is off-label, there is no official protocol recommended by the manufacturer. Instead, laboratories in which SurePath Pap specimens are used for HC2 HPV testing usually validate HC2 testing in their own laboratory. These laboratory validations are rarely published. Consequently, there is no standardized HC2 HPV testing protocol for SurePath Pap specimens, which may explain the relatively lower accuracy of HC2 testing in cell lines fixed in SurePath medium (96.2%) than in ThinPrep medium (98%), as seen in the HPV proficiency testing performed by the College of American Pathologists.
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Although the off-label use of the HC2 assay in SurePath specimens may have intrinsic weaknesses for HPV detection, the availability of up-to-date published clinical studies comparing the clinical performance of the HC2 assay in SurePath and ThinPrep specimens is limited. Therefore, there is little convincing evidence that the clinical performance of HC2 in SurePath specimens is significantly lower than that seen in ThinPrep specimens. In a prospective clinical study evaluating the clinical performance of HC2 HPV testing in SurePath and ThinPrep Pap specimens, Zhao et al 40 reported comparable HC2 clinical sensitivities in paired sampling of SurePath (91%) and ThinPrep (89%) specimens. Ko et al 41 also reported that HC2 had comparable sensitivity in SurePath and ThinPrep specimens. Siddiqi et al 42 reported an indirect comparison of HC2 HPV testing in SurePath and ThinPrep specimens in a screening population and found no statistical difference in ageadjusted HPV positivity or in the rate of CIN 2/3 positivity on biopsy follow-up between the two liquid-based Pap specimens.
Comparison of HC2 false-negative rates in SurePath and ThinPrep specimens can also provide indirect evidence of the clinical performance of HC2 HPV testing. In a 3-year follow-up study at our institution for patients with negative SurePath Pap and negative HC2 results, we observed a low follow-up rate for CIN 3 (0.17%; M.G., unpublished data). Zhao et al 43 reported a similar CIN 3 rate (0.17%) with a mean follow-up period of 44 months for women with negative ThinPrep Pap and negative HC2 HPV testing results. Nevertheless, current guidelines for cervical cancer screening issued by the ASCCP and American College of Obstetricians and Gynecologists advise against unapproved off-label use of HPV testing. 9, 10 Studies directly comparing the two liquid-based cytology collecting media for HPV testing or large-scale follow-up studies to compare ageadjusted clinical sensitivities of HC2 HPV testing assays in SurePath and ThinPrep specimens are necessary to clarify the issue of whether the false-negative rate for HC2 HPV testing in SurePath specimens is higher than that in ThinPrep specimens.
In our cohort of 100 Pap specimens, 44 were vaginal Pap specimens. Published data on HC2 testing in vaginal Pap test specimens are scant. Castle et al 44 compared HPV testing (PCR and type-specific dot blot hybridization) in cervical and vaginal Pap specimens and reported a similar prevalence of carcinogenic HPV types in both types of specimens. Bansal et al 45 reported a higher rate of vaginal squamous intraepithelial lesions in women with ASC-US/ HC2-positive results (47.8%) than in women with ASC-US/ HC2-negative results (4.7%), indicating the usefulness of HC2 testing in triage of women with ASC-US. In our cohort, it appeared that HC2 efficacy was lower in vaginal Pap test specimens than in cervical Pap test specimens. However, the small size of our cohort precluded any valid comparison.
Our findings suggest that, for long-term follow-up monitoring in a relatively older patient population, HC2 testing may not be as effective as it is in a screening population for triaging patients with ASC-US for colposcopic evaluation. Because of a relatively high false-negative rate, HC2 HPV testing alone may not be sufficient for posttherapy follow-up. Furthermore, an ASC-US Pap result may be sufficient to warrant colposcopic evaluation during posttherapy follow up, depending on the specific clinical setting. For instance, in the 7 patients in our cohort with ASC-US/HC2-negative results and CIN/VAIN 2þ follow-up biopsy results, 6 had previous abnormal Pap or biopsy results (Table 4) , the Pap result of ASC-US triggered colposcopic evaluation even though HC2 test was negative. Persistence of HPV infection or HPV 16/18 genotyping may be a better indicator of recurrent CIN 2þ during long-term posttherapy follow-up. 17, 46, 47 However, the cost-effectiveness of these strategies as triage tools to predict recurrent/ residual CIN/VAIN 2þ in patients with an ASC-US Pap result in the long-term follow-up setting needs further evaluation.
The main limitation of our study is that it is retrospective, with patient heterogeneity that included different types of cervical/vaginal precancerous lesions/carcinoma and a variety of therapies. Furthermore, our study cohort was relatively small. Finally, for most patients, residual Pap test specimens were not available to verify HPV status, which is necessary to confirm false-negative HC2 results. Further studies are necessary to determine the efficacy of HPV and
